GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Short Interest

Veracyte (FRA:12V) Short Interest


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Veracyte's Short Interest

For the Diagnostics & Research subindustry, Veracyte's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veracyte's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Short Interest distribution charts can be found below:

* The bar in red indicates where Veracyte's Short Interest falls into.


;
;

Veracyte Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Short Interest
Comparable Companies
TWST WGS NEOG SHC NEO OPK RDNT CDNA GRAL MYGN TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA
Traded in Other Exchanges
VCYT:USA
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.veracyte.com
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Veracyte Headlines

No Headlines